|
|
 |
|
|
|
|
|
|
|
|
|
 |
 |
||||||||
 |
 |
 |
 |
 |
 |
 |
|
||
|
|
|
|
|
|||||||
 |
 |
|
|
||||||||
|
Malcolm J. Moore, MD, FRCPC
His major interest over the past 10 years has been innovative drug development for cancer therapy. He has been a principal investigator for many phase I, II and III studies in gastrointestinal and genitourinary cancer supported by NCI, NCIC and the pharmaceutical industry. He has been instrumental in the development of a number of agents that have subsequently been approved for clinical usage such as mitoxantrone in hormone refractory prostate cancer and gemcitabine in both pancreatic and urothelial cancer. Dr Moore has 90 peer reviewed publications and has given over 100 invited lectures.
|
|
Dr. Moore is a Professor of Medicine and Pharmacology in the Department
of Medical Oncology and Hematology at Princess Margaret Hospital, University
of Toronto and a Senior Scientist in the Division of Experimental Therapeutics
at the Ontario Cancer Institute. He is chair of the GI Cancer Program
at PMH and was recently appointed Chair of the GI committee for National
Cancer Institute of Canada [NCIC]. Dr Moore is Director of the Drug Development
Program at PMH and heads the PMH Phase II Consortium, an alliance of 3
hospitals, PMH, Hamilton and London Regional Cancer Centres that won a
contract with NCI ensuring access to new NCI anti-cancer drugs.